Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 14/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.47 |
| ▸ | FAP | Q12884 | 3/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.47 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296935 | 1.00 | DPP4 (0.47) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL1951493 | 1.00 | DPP4 (0.47) | DPP4DPP7DPP8DPP9FAP | |
| Hydrochloric Acid SCHEMBL25318201 | 0.98 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| Hydrochloric Acid SCHEMBL9512282 | 0.98 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL19982029 | 0.98 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL15203539 | 0.98 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL2735523 | 0.98 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| Hydrochloric Acid SCHEMBL9512271 | 0.98 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL9102765 | 0.95 | DPP4 (0.47) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL9102749 | 0.95 | DPP4 (0.47) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1731 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713780-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-01-18 | — | — | EP | claimed |
| US-20110294735-A1 | MECHANISM OF NEUROMEDIN U ACTION AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2011-12-01 | — | — | US | claimed |
| JP-4806628-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| EP-2352512-A1 | MECHANISM OF NEUROMEDIN U ACTION AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2011-08-10 | — | — | EP | claimed |
| US-20110091429-A1 | Methods for Enhancing Stem Cell Engraftment During Transplantation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-21 | — | — | US | claimed |
| EP-1911756-B9 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARM INC (US) | 2010-05-26 | — | — | EP | claimed |
| WO-2010053830-A1 | MECHANISM OF NEUROMEDIN U ACTION AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2010-05-14 | — | — | WO | claimed |
| EP-1620091-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-03-31 | — | — | EP | claimed |
| US-7655684-B2 | 1-(Urea-, thiourea- and cyanoguanidine-methylene)benzyl)imidaoles, treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson's disease and Huntington's disease | PROBIODRUG AG (DE) | 2010-02-02 | — | — | US | claimed |
| WO-2009152186-A1 | METHODS FOR ENHANCING CELL THERAPY EFFICACY INCLUDING TREATMENT WITH CD26 PEPTIDASE INHIBITORS | AMERICAN STEM CELL, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-20060205727-A1 | Combination therapy for endothelial dysfunction, angina and diabetes | HONG KONG NITRIC OXIDE LIMITED (HK) | 2006-09-14 | — | — | US | claimed |
| WO-2006086727-A2 | TREATING DIABETES WITH GLUCAGON-LIKE PEPTIDE-1 SECRETAGOGUES | ENTELOS, INC. (US) | 2006-08-17 | — | — | WO | claimed |
| EP-1620091-A2 | INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2006-02-01 | — | — | EP | claimed |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | PROBIODRUG AG | 2005-09-29 | — | — | US | claimed |
| US-20050203030-A1 | Novel effectors of dipeptidyl peptidase IV | PROSIDION LIMITED (GB) | 2005-09-15 | — | — | US | claimed |
| WO-2005075436-A2 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2005-08-18 | — | — | WO | claimed |
| US-6890905-B2 | Methods for improving islet signaling in diabetes mellitus and for its prevention | PROSIDION LIMITED (GB) | 2005-05-10 | — | — | US | claimed |
| US-20040247574-A1 | Methods for enhancing stem cell engraftment during transplantation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-12-09 | — | — | US | claimed |
| WO-2004098591-A2 | INHIBITORS OF GLUTAMINYL CYCLASE AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | PROBIODRUG AG (DE) | 2004-11-18 | — | — | WO | claimed |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2004-11-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | DPP4 2056/4885DPP7 1896/4885DPP8 2739/4885 |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | DPP4 1062/4885DPP7 1485/4885DPP8 1718/4885 |
| US-20060205727-A1 | Combination therapy for endothelial dysfunction, angina and diabetes | DPP4, PRKCSH, PC | DPP4 1/4885DPP7 17/4885DPP8 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.